NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
53 hedge funds and large institutions have $49M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
6% more funds holding
Funds holding: 50 → 53 (+3)
4% less capital invested
Capital invested by funds: $51M → $49M (-$1.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prelude Capital Management
New York
|
+$2.52M |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
+$482K |
| 3 |
D.E. Shaw & Co
New York
|
+$333K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$322K |
| 5 |
JP Morgan Chase
New York
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.14M |
| 2 |
Renaissance Technologies
New York
|
-$1.09M |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$324K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$273K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$259K |
NBSE Hedge Fund Activity: Q4 2020 in Review
53 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2020, worth a combined $49M — down 3.8% from $51M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NBSE positions and 7 closed out — a net gain of 3 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Prelude Capital Management, opening a new position worth an estimated $2.52M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.14M sold.
- 53 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2020, up from 50 in Q3 2020.
- Funds reported $49M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2020, down 3.8% quarter-over-quarter.
- 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of +3 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2020 was Prelude Capital Management, an estimated $2.52M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2020 was Sphera Funds Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q4 2020.